$2.16
1.82%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
US16385C1045
Symbol
CMMB

Chemomab Therapeutics Ltd - ADR Target price 2026 - Analyst rating & recommendation

Chemomab Therapeutics Ltd - ADR Classifications & Recommendation

Buy
88%
Hold
13%

Chemomab Therapeutics Ltd - ADR Price Target

Target Price $15.30
Price $2.16
Potential
Number of Estimates 4
4 Analysts have issued a price target Chemomab Therapeutics Ltd - ADR 2027 . The average Chemomab Therapeutics Ltd - ADR target price is $15.30. This is higher than the current stock price. The highest price target is
$26.25 1,115.28%
register free of charge
, the lowest is .
A rating was issued by 8 analysts: 7 Analysts recommend Chemomab Therapeutics Ltd - ADR to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Chemomab Therapeutics Ltd - ADR stock has an average upside potential 2027 of . Most analysts recommend the Chemomab Therapeutics Ltd - ADR stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ -0.02 -0.53
87.50% 2,550.00%
P/E negative

4 Analysts have issued a Chemomab Therapeutics Ltd - ADR forecast for earnings per share. The average Chemomab Therapeutics Ltd - ADR EPS is

$-0.53
unlock
. This is
5,200.00% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-0.02 100.00%
unlock
, the lowest is
$-1.00 9,900.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.02 87.50%
2026
$-0.53 2,550.00%
unlock
2027
$-0.61 15.09%
unlock
2028
$-0.57 6.56%
unlock
2029
$-0.04 92.98%
unlock
2030
$-0.04 0.00%
unlock
2031
$1.88 4,800.00%
unlock
2032
$2.98 58.51%
unlock

P/E ratio

Current -216.00 715.09%
2026
-4.07 98.12%
unlock
2027
-3.56 12.53%
unlock
2028
-3.82 7.30%
unlock
2029
-52.94 1,285.86%
unlock
2030
-52.94 0.00%
unlock

Current Chemomab Therapeutics Ltd - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Oppenheimer
Locked
➜
Locked
Locked Aug 27 2025
Oppenheimer
Locked
➜
Locked
Locked May 16 2025
Maxim Group
Locked
➜
Locked
Locked Feb 20 2025
Oppenheimer
Locked
➜
Locked
Locked Nov 15 2024
Analyst Rating Date
Locked
Oppenheimer:
Locked
➜
Locked
Aug 27 2025
Locked
Oppenheimer:
Locked
➜
Locked
May 16 2025
Locked
Maxim Group:
Locked
➜
Locked
Feb 20 2025
Locked
Oppenheimer:
Locked
➜
Locked
Nov 15 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today